1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Clindamycin Hydrochloride Capsules
Trade Name: Cleocin; Dalacin; SOBELIN; DALACINE ; DALACIN C
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet
Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification
Serious Eye Damage/Eye Irritation: Category 2A
Skin Sensitization: Category 1

Label Elements

Signal Word: Warning
Hazard Statements: H319 - Causes serious eye irritation
H317 - May cause an allergic skin reaction

Precautionary Statements: P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P264 - Wash hands thoroughly after handling
P272 - Contaminated work clothing must not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
P337 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental instructions on the administration of antidotes on this label)
P363 - Wash contaminated clothing before reuse
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Talc (non-asbestiform)</td>
<td>14807-96-6</td>
<td>238-877-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Corn Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Clindamycin Hydrochloride</td>
<td>21462-39-5</td>
<td>244-398-6</td>
<td>Eye Irrit. 2A (H319) Skin Sens.1 (H317)</td>
<td>20-30.2</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon, nitrogen, sulfur, and chlorine.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters
During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Wash hands and any exposed skin after removal of PPE. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.
## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Talc (non-asbestiform)

<table>
<thead>
<tr>
<th>Material</th>
<th>ACGIH Threshold Limit Value (TWA)</th>
<th>Australia TWA</th>
<th>Austria OEL - MAKs</th>
<th>Belgium OEL - TWA</th>
<th>Bulgaria OEL - TWA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2.5 mg/m³</td>
<td>2 mg/m³</td>
<td>2 mg/m³</td>
<td>1.0 fiber/cm³</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.0 mg/m³</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.0 mg/m³</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td></td>
<td>2.0 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denmark OEL - TWA</td>
<td></td>
<td>0.3 fiber/cm³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland OEL - TWA</td>
<td></td>
<td>0.5 fiber/cm³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td></td>
<td>10 mg/m³</td>
<td>2 mg/m³</td>
<td>0.8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Hungary OEL - TWA</td>
<td></td>
<td>2 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td></td>
<td>10 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td></td>
<td>2 mg/m³</td>
<td>1 mg/m³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Netherlands OEL - TWA</td>
<td></td>
<td>0.25 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSHA - Final PELs - Table Z-3 Mineral D:</td>
<td></td>
<td>20 mppcf</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td></td>
<td>4.0 mg/m³</td>
<td>1.0 mg/m³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td></td>
<td>2 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romania OEL - TWA</td>
<td></td>
<td>2 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td></td>
<td>2 mg/m³</td>
<td>10 mg/m³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenia OEL - TWA</td>
<td></td>
<td>2 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td></td>
<td>2 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden OEL - TWAs</td>
<td></td>
<td>2 mg/m³</td>
<td>1 mg/m³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td></td>
<td>2 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Corn Starch

<table>
<thead>
<tr>
<th>Material</th>
<th>ACGIH Threshold Limit Value (TWA)</th>
<th>Australia TWA</th>
<th>Belgium OEL - TWA</th>
<th>Bulgaria OEL - TWA</th>
<th>Czech Republic OEL - TWA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>10 mg/m³</td>
<td>10 mg/m³</td>
<td>10 mg/m³</td>
<td>4.0 mg/m³</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td></td>
<td>10 mg/m³</td>
<td>4 mg/m³</td>
<td></td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>OSHA - Final PELs - TWAs:</td>
<td></td>
<td>15 mg/m³</td>
<td>10 mg/m³</td>
<td>4 mg/m³</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td></td>
<td>10 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td></td>
<td>4 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td></td>
<td>10 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td></td>
<td>3 mg/m³</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Clindamycin Hydrochloride

<table>
<thead>
<tr>
<th>Material</th>
<th>Pfizer OEL TWA-8 Hr</th>
<th>100 µg/m³</th>
</tr>
</thead>
</table>

### Magnesium stearate
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Exposure Controls</th>
<th>Engineering Controls:</th>
<th>Personal Protective Equipment:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.</td>
<td>Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.</td>
</tr>
<tr>
<td>Hands:</td>
<td>Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)</td>
<td></td>
</tr>
<tr>
<td>Eyes:</td>
<td>Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)</td>
<td></td>
</tr>
<tr>
<td>Skin:</td>
<td>Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)</td>
<td></td>
</tr>
<tr>
<td>Respiratory protection:</td>
<td>Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)</td>
<td></td>
</tr>
</tbody>
</table>

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Capsule</th>
<th>Color:</th>
<th>Green (75 mg), Light blue / green (150 mg), light blue (300 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available.</td>
<td>Odor Threshold:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clindamycin Hydrochloride
No data available

Lactose
No data available

Talc (non-asbestiform)
No data available

Magnesium stearate
No data available

Corn Starch
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Sweden OEL - TWAs
5 mg/m³

Lithuania OEL - TWA
5 mg/m³

Clindamycin Hydrochloride Capsules

Revision date: 31-Jul-2018

Version: 4.1
### 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>No data available</td>
</tr>
<tr>
<td>Chemical Stability</td>
<td>Stable under normal conditions of use.</td>
</tr>
<tr>
<td>Possibility of Hazardous Reactions</td>
<td>No data available</td>
</tr>
<tr>
<td>Oxidizing Properties</td>
<td>No data available</td>
</tr>
<tr>
<td>Conditions to Avoid</td>
<td>Fine particles (such as dust and mists) may fuel fires/explosions.</td>
</tr>
<tr>
<td>Incompatible Materials</td>
<td>As a precautionary measure, keep away from strong oxidizers</td>
</tr>
<tr>
<td>Hazardous Decomposition Products</td>
<td>No data available</td>
</tr>
</tbody>
</table>

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:**
The information included in this section describes the potential hazards of the individual ingredients.

**Known Clinical Effects:**
Adverse effects associated with therapeutic use include gastrointestinal disturbances such as nausea, dyspepsia, and vomiting and gastrointestinal irritation. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

#### Acute Toxicity: (Species, Route, End Point, Dose)

**Clindamycin Hydrochloride**

- **Rat** Oral LD 50 2618 mg/kg
- **Rat** Sub-tenon injection (eye) LD 50 279 mg/kg
- **Rat** Subcutaneous LD 50 891 mg/kg
- **Mouse** Oral LD 50 1479 mg/kg
- **Mouse** Intravenous LD 50 143 mg/kg

**Talc (non-asbestiform)**

- **Rat** Oral LD 50 > 1600 mg/kg

**Magnesium stearate**

- **Rat** Oral LD 50 > 2000 mg/kg
- **Rat** Inhalation LC 50 > 2000 mg/m³

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**
11. TOXICOLOGICAL INFORMATION

Clindamycin Hydrochloride

Eye Irritation  Rat  No effect
Eye Irritation  Rabbit  Moderate
Skin Irritation  Rat  No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Hydrochloride

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Month(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>600 mg/kg/day</td>
<td>NOAEL</td>
<td>No effects at maximum dose</td>
</tr>
<tr>
<td>6 Month(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>600 mg/kg/day</td>
<td>LOAEL</td>
<td>Gastrointestinal system</td>
</tr>
<tr>
<td>1 Year(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>300 mg/kg/day</td>
<td>NOAEL</td>
<td>No effects at maximum dose</td>
</tr>
<tr>
<td>1 Month(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>300 mg/kg/day</td>
<td>NOAEL</td>
<td>No effects at maximum dose</td>
</tr>
</tbody>
</table>

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Hydrochloride

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>NOAEL</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reproductive &amp; Fertility</td>
<td>Rat</td>
<td>Oral</td>
<td>300 mg/kg/day</td>
<td>NOAEL</td>
<td>Fertility</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Mouse</td>
<td>Oral</td>
<td>600 mg/kg/day</td>
<td>NOAEL</td>
<td>Not Teratogenic</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>Oral</td>
<td>600 mg/kg/day</td>
<td>NOAEL</td>
<td>Not Teratogenic</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>250 mg/kg/day</td>
<td>NOAEL</td>
<td>Not Teratogenic</td>
</tr>
</tbody>
</table>

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Hydrochloride

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Cell Type/Organism</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td>Salmonella</td>
<td>Negative</td>
</tr>
<tr>
<td>In Vitro Micronucleus</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Talc (non-asbestiform)

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Lactose
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register:
  - EU EINECS/ELINCS List: 200-559-2

Talc (non-asbestiform)
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 238-877-9

Corn Starch
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register:
  - EU EINECS/ELINCS List: 232-679-6

PZ00138
15. REGULATORY INFORMATION

Clindamycin Hydrochloride
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- EU EINECS/ELINCS List: 244-398-6

Magnesium stearate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 209-150-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3
- Acute toxicity, oral-Cat.5; H303 - May be harmful if swallowed
- Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation
- Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Data Sources:
- Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision:
- Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date:
- 31-Jul-2018

Prepared by:
- Product Stewardship Hazard Communication
- Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet